IP Library Granted Patent US 10,456,473
Granted Patent B2
US 10,456,473 · App. 15/594,244 · Granted Oct 29, 2019

Lipid compositions

Inventors: Muthiah Manoharan (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); David Butler (Medford, MA); Michael E. Jung (Cambridge, MA)
Assignee: Arbutus Biopharma Corporation
A61K47/22A61K9/1272C07D295/13C12N15/113C12N15/1137C12N2310/14Y02A50/463
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,473
App. No.
15/594,244
Granted
Oct 29, 2019
Kind
B2
Abstract

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).

Claims (19)

1. A method of making a compound of formula (IV)

wherein each R is independently H, alkyl,

 provided that at least one R is

R 1 , for each occurrence, is independently H, R 3 ,

 wherein R 3 is optionally substituted with one or more substituent;

R 2 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl; each of which is optionally substituted with one or more substituent;

R 3 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl; each of which is optionally substituted with one or more substituent;

Y, for each occurrence, is independently, O, NR 4 , or S;

R 4 , for each occurrence, is independently, H alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl; each of which is optionally substituted with one or more substituent;

the method comprising contacting an enantiomerically enriched β-hydroxyalkyl synthetic equivalent that is a precursor to R, wherein the functional groups provided by the β-hydroxyalkyl synthetic equivalent undergo further reactions to afford the final R group(s) in the compound of formula (IV), the β-hydroxyalkyl group being optionally substituted with one or more substituent, with a compound of formula (VIII)

wherein R 5 , for each occurrence, is independently, H, alkyl, or an amine protecting group, wherein alkyl is optionally substituted with one or more substituent; and R 6 , for each occurrence, is independently, H, —(CH 2 ) 2 N(R 5 ) 2 , or an amine protecting group.

2. The method of claim 1 , wherein the compound of formula (VIII) is

or a mixture thereof.

3. The method of claim 1 , wherein the enantiomerically enriched β-hydroxyalkyl synthetic equivalent includes an enantiomerically enriched 1,2-epoxyalkane.

4. The method of claim 3 , wherein the enantiomerically enriched 1,2-epoxyalkane is (R)-1,2-epoxydodecane.

5. The method of claim 1 , wherein the enantiomerically enriched β-hydroxyalkyl synthetic equivalent includes a protected a-hydroxyaldehyde.

6. The method of claim 5 , wherein the protected a-hydroxyaldehyde is 2-(O-Pg)-dodecanal, wherein O-Pg represents a protected hydroxyl group.

7. The method of claim 1 , further comprising contacting a primary alcohol trapping reagent with a product of a reaction between the enantiomerically enriched β-hydroxyalkyl synthetic equivalent and the compound of formula (VIII).

8. The method of claim 1 , further comprising contacting 1-(2-(phthalimido)ethyl)-piperazine with 1-(2-chloroethyl)imidazolidin-2-one.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Jul 27, 2018
From: PROTIVA BIOTHERAPEUTICS INC.; ARBUTUS BIOPHARMA CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 046640/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2017
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; JAYARAMAN, MUTHUSAMY; BUTLER, DAVID; JUNG, MICHAEL E.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 043263/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2017
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 043263/0408 →
CHANGE OF NAME Recorded Aug 10, 2017
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 043263/0427 →
Continuity (5)
Continuation 14508805 · Oct 7, 2014
Continuation 13318600
Provisional Application 61175770 · May 5, 2009
Provisional Application 61299291 · Jan 28, 2010
Related Publication 20180104342A1 · Apr 19, 2018
Cited By (1)
US 12,409,211